To date, five patients have completed four weeks of treatment, and ACH-3102 has been well tolerated, with no serious adverse events...No serious adverse events were reported, and the drug demonstrated a dose-dependent lowering effect on growth hormone (hGH), as shown by an analysis of the pharmacodynamics effect on hGH, when stimulated by growth hormone-releasing hormone

iCo Therapeutics Inc., of Vancouver, British Columbia, said there have been no drug-related serious adverse events among patients receiving repeat doses of iCo-007 at the midpoint of its Phase II iDEAL study in diabetic macular edema

Zogenix Inc., of San Diego, reported single-dose pharmacokinetic results from a Phase I trial testing Relday, a once-monthly subcutaneous formulation of risperidone for treating schizophrenia, showing that adverse events were generally mild to moderate and consistent with other risperidone products

The primary endpoint is disease control rate at 16 weeks, while secondary endpoints will include the incidence and severity of adverse events, global DNA methylation levels, methylation status of selected tumor suppressor genes in tumor tissue, progression-free survival and overall survival

No serious or unexpected adverse events occurred, and the drug's pharmacodynamic behavior was consistent with expectations

There was also a statistically significant increase in some nonfatal serious adverse events in the group receiving extended-release niacin/laropiprant

The study enrolled 2,051 subjects at 127 sites in 13 countries, and was designed to evaluate safety and efficacy, with a primary endpoint of mortality or death over two years, and a secondary endpoint of treatment emergent adverse events

The authors reported that Novavax' vaccine was well tolerated, with no evident dose-related toxicity or attributable severe adverse events...Safety results were consistent with other testosterone therapies, and there were no drug-related adverse events

UCB SA, of Brussels, Belgium, said a subgroup analysis of pooled data from three long-term open-label extension trials showed a consistent safety profile with epilepsy drug Vimpat (lacosamide), with the most commonly reported treatment-emergent adverse events being dizziness, headache and nasopharyngitis

Single doses up to 7.5 mg were generally well tolerated, with no significant adverse events

The vaccine regimen was given to patients with metastatic pancreatic cancer, and it was well tolerated with no unexpected adverse events...The most common adverse events were rash, thrombocytopenia, arthralgia, increased lipase, fatigue, acneiform dermatitis, dry skin and nausea

Oxford BioMedica plc, of Oxford, UK, and partner Sanofi SA, of Paris, disclosed a positive interim review of the ongoing UshStat Phase I/IIa study by the data safety monitoring board (DSMB), with no serious adverse events in the three patients treated at dose level one related to the product

Bio-Path reported that the drug's safety profile continued to be favorable, with no treatment-related serious adverse events reported, and data continue to suggest some possible anti-leukemia activity...Its most frequent adverse events were pain, infection and insomnia

The most common adverse events included fatigue, rash, diarrhea, nausea, cough, joint pain, fever and itching, with seven MK-3475-related Grade 3/4 adverse events potentially immune related

The overall incidence of adverse events (AEs) was generally similar across all treatment arms

Enrollees in the study each received the first of a four-dose vaccine regimen and were followed for three hours, with no adverse events observed

The most common reported adverse events were nasopharyngitis, cough and nausea

primary safety measures include serious adverse events, adverse events and major bleeding events

The L-PPDS was well tolerated over the testing period with adverse events similar to those reported for commercial punctal plugs and a previous PPL GLAU 11 study